Samenvatting
Magnetische resonantie imaging (MRI) is een vorm van radiologische beeldvorming waarbij geen röntgenstraling maar radiofrequente golven gebruikt worden om wekedelenweefsels in het lichaam af te beelden. Het gebied van het kleine bekken, waarin zich ook de prostaat bevindt, is hiervoor uitstekend geschikt. Er wordt steeds vaker een MRI-scan verricht bij patiënten met (een verdenking op) prostaatkanker. Om inzicht te krijgen in de mogelijkheden van MRI bij prostaatkanker, is het van belang eerst enige informatie te verschaffen over de anatomie van de prostaat en de pathologie van prostaatkanker, alsook over de overige diagnostische hulpmiddelen en mogelijke therapiekeuzes.
Literatuur
IKNL. Cijfers over kanker. http://www.cijfersoverkanker.nl/. Geraadpleegd op 29 maart 2016.
McNeal JE. Normal anatomy of the prostate and changes in benign prostatic hypertrophy and carcinoma. Semin Ultrasound CT MR. 1988;9(5):329–34.
Chen ME, Johnston DA, Tang K, Babaian RJ, Troncoso P. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer. 2000;89(8):1800–9.
Miller GJ, Cygan JM. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol. 1994;152(5 Pt 2):1709–13.
McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988;12(12):897–906.
Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol. 1992;23(3):273–9.
Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Prognostic value of the Gleason score in prostate cancer. BJU Int. 2002;89(6):538–42.
McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Capsular penetration in prostate cancer. Significance for natural history and treatment. Am J Surg Pathol. 1990;14(3):240–7.
Ohori M, Scardino PT, Lapin SL, Seale-Hawkins C, Link J, Wheeler TM. The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am J Surg Pathol. 1993;17(12):1252–61.
Saitoh H, Yoshida K, Uchijima Y, Kobayashi N, Suwata J, Kamata S. Two different lymph node metastatic patterns of a prostatic cancer. Cancer. 1990;65(8):1843–6.
Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106(7):1624–33.
Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm M‑O, et al. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol. 2011;60(2):291–303.
Velonas VM, Woo HH, Remedios CG dos, Assinder SJ. Current status of biomarkers for prostate cancer. Int J Mol Sci. 2013;14(6):11034–60.
Kuriyama M, Wang MC, Papsidero LD, Killian CS, Shimano T, Valenzuela L, et al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res. 1980;40(12):4658–62.
Ellis WJ, Brawer MK. The significance of isoechoic prostatic carcinoma. J Urol. 1994;152(6 Pt 2):2304–7.
Gore JL, Shariat SF, Miles BJ, Kadmon D, Jiang N, Wheeler TM, et al. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol. 2001;165(5):1554–9.
Scherr DS, Eastham J, Ohori M, Scardino PT. Prostate biopsy techniques and indications: when, where, and how? Semin Urol Oncol. 2002;20(1):18–31.
King CR, McNeal JE, Gill H, Presti JC. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients. Int J Radiat Oncol Biol Phys. 2004;59(2):386–91.
Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011;59(4):477–94.
Fütterer JJ, Heijmink SWTPJ, Scheenen TWJ, Jager GJ, Hulsbergen-Van de Kaa CA, Witjes JA, et al. Prostate cancer: local staging at 3‑T endorectal MR imaging – early experience. Radiology. 2006;238(1):184–91.
Heijmink SWTPJ, Fütterer JJ, Hambrock T, Takahashi S, Scheenen TWJ, Huisman HJ, et al. Prostate cancer: body-array versus endorectal coil MR imaging at 3 T – comparison of image quality, localization, and staging performance. Radiology. 2007;244(1):184–95.
Hövels AM, Heesakkers RAM, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63(4):387–95.
Barrett T, Vargas HA, Akin O, Goldman DA, Hricak H. Value of the hemorrhage exclusion sign on T1-weighted prostate MR images for the detection of prostate cancer. Radiology. 2012;263(3):751–7.
Vargas HA, Lawrence EM, Mazaheri Y, Sala E. Updates in advanced diffusion-weighted magnetic resonance imaging techniques in the evaluation of prostate cancer. World J Radiol. 2015;7(8):184–8.
Hambrock T, Somford DM, Huisman HJ, Oort IM van, Witjes JA, Hulsbergen-van de Kaa CA, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology. 2011;259(2):453–61.
Hötker AM, Mazaheri Y, Aras Ö, Zheng J, Moskowitz CS, Gondo T, et al. Assessment of prostate cancer aggressiveness by use of the combination of quantitative DWI and dynamic contrast-enhanced MRI. AJR Am J Roentgenol. 2016;206(4):756–63.
Hoeks CMA, Barentsz JO, Hambrock T, Yakar D, Somford DM, Heijmink SWTPJ, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology. 2011;261(1):46–66.
Vos EK, Kobus T, Litjens GJS, Hambrock T, Hulsbergen-van de Kaa CA, Barentsz JO, et al. Multiparametric magnetic resonance imaging for discriminating low-grade from high-grade prostate cancer. Invest Radiol. 2015;50(8):490–7.
Fütterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol. 2015;68(6):1045–53.
Thompson JE, Leeuwen PJ van, Moses D, Shnier R, Brenner P, Delprado W, et al. The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer. J Urol. 2016;195(5):1428–35.
Hoeks CMA, Hambrock T, Yakar D, Hulsbergen-van de Kaa CA, Feuth T, Witjes JA, et al. Transition zone prostate cancer: detection and localization with 3‑T multiparametric MR imaging. Radiology. 2013;266(1):207–17.
Steenbergen P, Haustermans K, Lerut E, Oyen R, De Wever L, Van den Bergh L, et al. Prostate tumor delineation using multiparametric magnetic resonance imaging: Inter-observer variability and pathology validation. Radiother Oncol. 2015;115(2):186–90.
Dinh CV, Steenbergen P, Ghobadi G, Heijmink SWTJP, Pos FJ, Haustermans K, et al. Magnetic resonance imaging for prostate cancer radiotherapy. Phys Med. 2016;32(3):446–51.
Scheenen TWJ, Heijmink SWTPJ, Roell SA, Hulsbergen-Van de Kaa CA, Knipscheer BC, Witjes JA, et al. Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology. 2007;245(2):507–16.
Pondman KM, Fütterer JJ, Haken B ten, Schultze Kool LJ, Witjes JA, Hambrock T, et al. MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur Urol. 2008;54(3):517–27.
ACR, PI-RADS v2. 2015 http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/PIRADS/PIRADS%20V2.pdf.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Heijmink, S. Het gebruik van MRI-scan bij prostaatkanker. Bijblijven 32, 234–251 (2016). https://doi.org/10.1007/s12414-016-0136-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12414-016-0136-3